Navigation Links
Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
Date:8/23/2010

PRINCETON, N.J., Aug. 23 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that it has been awarded a three year $1.2 million clinical research grant by the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) pursuant to its Orphan Products Development (OPD) Program.

The grant will be used  to defray a significant portion of the costs associated with the conduct of the Company's ongoing, confirmatory, Phase 3 clinical trial of orBec® in acute gastrointestinal Graft-versus-Host-Disease (GI GVHD).  This trial, also referred to as the SUPPORTS protocol (Sparing Unnecessary Prednisone Phase 3 orBec® Randomized Treatment Study), will enroll an estimated 166 subjects to confirm the clinically meaningful endpoints observed in previous Phase 2 and Phase 3 clinical studies. The primary endpoint in the SUPPORTS protocol is the treatment failure rate at Study Day 80. This endpoint was successfully measured as a secondary endpoint (p-value 0.005) in the Company's previous Phase 3 study as a key measure of durability following a 50-day course of treatment with orBec® (i.e., 30 days following cessation of treatment).  The Phase 3 study includes major stem cell transplantation centers in the United States, Europe and Australia, and is expected to complete in the first half of 2011.

"We are grateful to have been awarded this significant grant to support our ongoing confirmatory Phase 3 study," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "We believe the award is a validation of the design of our Phase 3 trial and a clear indicator of the importance of orBec® and its potential application in the treatment
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... MEMPHIS, Tenn. , Dec. 22, 2014   ... only automated, no-touch UV disinfection robot, announced today that ... GSA Schedule contract through November 2019.   ... to rapidly engage all levels of government purchasers, including ... facilities, as well as Homeland Security contacts purchasing solutions ...
(Date:12/22/2014)... , Dec. 22, 2014 Cyberonics, Inc. (NASDAQ: ... for the treatment and management of epilepsy, today announced it ... Healthcare Conference on Wednesday, January 14, 2015, in ... Cyberonics, President and Chief Executive Officer, will speak at 11:00 ... can be accessed by clicking on the Investor Relations link ...
(Date:12/22/2014)... Maine , Dec. 22, 2014  Mark ... analysis brief providing a summary of the 2015 ... plan enrollment trends.  According to ... for Planning and Evaluation, Department of Health and ... were enrolled in individual medical plans through the ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2Insights into the Marketplace and Individual Market Growth 2
(Date:12/26/2014)... 26, 2014 DW-InductionHeating.com (DaWei Induction Heating ... researching and developing, producing and marketing of a series ... business announces their new series of induction brazing ... the company, induction brazing refers to the ... filler material and heat. The manager says that there ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... December 26, 2014 Recently, Dylan Queen, ... has excitedly released its collection of discounted prom dresses, ... Percy, a senior spokesman of the company, the promotion ... this promotion is to expand the UK market. , ... several different colors, lengths, and styles: A-line strapless, empire ...
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... muscular atrophy , , THURSDAY, Jan. 10 (HealthDay News) -- ... pregnant with her second child. Her baby didn,t move, except ... leaving her stomach flat. , Her fears were confirmed ... weak cry, very little muscle tone, he had contractures in ...
... A protein found in human hair shows promise for ... a new treatment option when nerves are cut or crushed ... scientists from Wake Forest University School of Medicine reported that ... up nerve regeneration and improve nerve function compared to current ...
... federal, state levels to combat tobacco use, report says ... registered some significant gains in 2007, with more states ... too little federal and state funding for smoking-prevention and ... taxes. , That,s the conclusion of the American Lung ...
... Supported SelfCare,Inc., a national provider of disease ... awarded Full Disease Management Accreditation from URAC, ... establishes,quality standards for the healthcare industry., ... very seriously. This,national accreditation validates LifeMasters, clinical ...
... efforts through Consumer Innovation ... ... (NYSE:,WLP) is accepting applications for its first Consumer Innovation Event. The,event ... identifying and piloting innovative,programs and services., "The health benefits industry ...
... Jan. 9 Synergy Life Science,Partners, LP, a ... medical device technologies, today announced the successful,completion of ... of $143,million in committed capital. The firm has ... 2006 by John Onopchenko, Richard Stack, M.D., and ...
Cached Medicine News:Health News:Years-Long Search Unlocks Deadly Genetic Disease 2Health News:Years-Long Search Unlocks Deadly Genetic Disease 3Health News:Years-Long Search Unlocks Deadly Genetic Disease 4Health News:Protein in human hair shows promise for regenerating nerves 2Health News:Protein in human hair shows promise for regenerating nerves 3Health News:Smoke-Free Workplace Laws, Cigarette Taxes on the Rise 2Health News:Smoke-Free Workplace Laws, Cigarette Taxes on the Rise 3Health News:Smoke-Free Workplace Laws, Cigarette Taxes on the Rise 4Health News:LifeMasters Receives Full URAC Disease Management Accreditation 2Health News:LifeMasters Receives Full URAC Disease Management Accreditation 3Health News:WellPoint Announces Consumer Innovation Opportunity 2Health News:WellPoint Announces Consumer Innovation Opportunity 3Health News:Synergy Life Science Partners Closes $143M Debut Medical Device Fund 2Health News:Synergy Life Science Partners Closes $143M Debut Medical Device Fund 3
Revised Drug calibrator that replaces existing Drug calibrator - this product contains Lithium in addition to Digoxin, Phenobarbital, OPhenytoin, & Theophulline....
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
Liquichek Rheumatoid Factor Control is a liquid trilevel control designed to monitor rheumatoid factor testing procedures, including nephelometric and latex agglutination methods....
... The BD Macro-Vue RPR (Rapid Plasma ... Tear-drop Tests are nontreponemal testing procedures ... described in A Manual of Tests ... this manual are the most widely ...
Medicine Products: